Longboard Pharmaceuticals Performance dei guadagni passati

Il passato criteri di controllo 0/6

Gli utili di Longboard Pharmaceuticals sono diminuiti a un tasso annuo medio di -33.5%, mentre il settore Pharmaceuticals ha visto gli utili crescere a un tasso annuo di 1.2%.

Informazioni chiave

-33.5%

Tasso di crescita degli utili

13.1%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore	6.0%
Tasso di crescita dei ricavi	n/a
Rendimento del capitale proprio	-27.7%
Margine netto	n/a
Ultimo aggiornamento sui guadagni	30 Sep 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

Oct 15

My Strategy For Longboard Pharmaceuticals After Its Big Run

Aug 28

We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth

Jul 12

Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely

Mar 16

Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?

Oct 03

We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate

Dec 25

Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth

Sep 10

We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely

May 28

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans

Feb 11

Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation

Oct 27

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business

Jun 12

Longboard Pharmaceuticals EPS beats by $0.29

May 10

Ripartizione dei ricavi e delle spese

Come Longboard Pharmaceuticals guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

NasdaqGM:LBPH Ricavi, spese e utili (USD Millions )
Data	Guadagni	Spese G+A	Spese di R&S
30 Sep 24	-76	20	67
30 Jun 24	-65	17	56
31 Mar 24	-58	15	48
31 Dec 23	-54	13	44
30 Sep 23	-51	12	41
30 Jun 23	-49	12	40
31 Mar 23	-46	11	36
31 Dec 22	-44	10	35
30 Sep 22	-41	10	32
30 Jun 22	-36	10	27
31 Mar 22	-32	9	22
31 Dec 21	-28	8	20
30 Sep 21	-29	6	16
30 Jun 21	-25	5	13
31 Mar 21	-20	4	9

Guadagni di qualità: LBPH al momento non è redditizia.

Margine di profitto in crescita: LBPH al momento non è redditizia.

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: LBPH non è redditizia e le perdite sono aumentate negli ultimi 5 anni a un tasso pari a 33.5% all'anno.

Accelerare la crescita: Impossibile confrontare la crescita degli utili di LBPH nell'ultimo anno con la sua media quinquennale poiché al momento non è redditizia

Guadagni vs Settore: LBPH non è redditizia, il che rende difficile confrontare la crescita dei suoi utili dell'anno passato con il settore Pharmaceuticals ( 54.6% ).

Rendimento del capitale proprio

ROE elevato: LBPH ha un Return on Equity negativo ( -27.74% ), in quanto al momento non è redditizio.

Longboard Pharmaceuticals Performance dei guadagni passati

Il passato criteri di controllo 0/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Longboard Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Longboard Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Recent updates

Longboard Pharmaceuticals Initiates Phase 3 DEEp Ocean Study Evaluating Bexicaserin in Developmental and Epileptic Encephalopathies (DEEs)

Langkawi Corporation entered into an Agreement and Plan of Merger to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.4 billion.

Longboard Pharma's Lucrative Exit To Lundbeck Another Coup For Management

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

My Strategy For Longboard Pharmaceuticals After Its Big Run

Longboard Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Longboard Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

We Think Longboard Pharmaceuticals (NASDAQ:LBPH) Can Afford To Drive Business Growth

Longboard Pharmaceuticals, Inc.(NasdaqGM:LBPH) dropped from Russell Small Cap Comp Value Index

Longboard Pharmaceuticals, Inc. Receives Breakthrough Therapy Designation for Bexicaserin (LP352)

Longboard Pharmaceuticals, Inc. Announces Positive Interim Results from Its Ongoing 52-Week Open-Label Extension of the Pacific Study Evaluating Bexicaserin (Lp352)

Price target decreased by 7.2% to US$41.75

New major risk - Shareholder dilution

Longboard Pharmaceuticals, Inc., Annual General Meeting, May 23, 2024

Insufficient new directors

Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding from Farallon Capital Management, L.L.C.

Longboard Pharmaceuticals, Inc. announced that it has received $59.85 million in funding from Farallon Capital Management, L.L.C.

Longboard Pharmaceuticals: After Stellar Gains, A Period Of Relative Calm Seems Likely

New major risk - Revenue and earnings growth

Longboard Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Shareholder dilution

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $210 million.

Price target increased by 43% to US$28.67

Longboard Pharmaceuticals, Inc. Announces Positive Topline Data from the Pacific Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (Dees)

Longboard Pharmaceuticals Announces Initiation of First-In-Human Phase 1 Clinical Study of Lp659 in Adult Healthy Volunteers

New minor risk - Market cap size

New minor risk - Share price stability

Will Longboard Pharmaceuticals (NASDAQ:LBPH) Spend Its Cash Wisely?

Longboard Pharmaceuticals, Inc. Completes Enrollment of Phase 1b/2a Pacific Study Evaluating LP352 for the Treatment of Developmental and Epileptic Encephalopathies

New major risk - Financial position

Price target decreased by 14% to US$17.00

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $20 million.

Longboard Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $20 million.

High number of new and inexperienced directors

We're Keeping An Eye On Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Rate

Longboard Pharmaceuticals Announces Positive Topline Data from A Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics and Pharmacodynamics of LP352 in Healthy Volunteers

Companies Like Longboard Pharmaceuticals (NASDAQ:LBPH) Are In A Position To Invest In Growth

We're Hopeful That Longboard Pharmaceuticals (NASDAQ:LBPH) Will Use Its Cash Wisely

Price target decreased to US$19.74

Price target decreased to US$22.80

Longboard Pharmaceuticals, Inc., Annual General Meeting, May 24, 2022

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not At All Concerned With Longboard Pharmaceuticals' (NASDAQ:LBPH) Cash Burn Situation

Longboard Pharmaceuticals Successfully Completes LP352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial

Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business

Longboard Pharmaceuticals Provides Corporate Update

Longboard Pharmaceuticals EPS beats by $0.29

Ripartizione dei ricavi e delle spese

Storia dei guadagni e delle entrate

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Rendimento del capitale proprio

Rendimento delle attività

Rendimento del capitale investito

Scoprire le aziende con forti performance passate